Literature DB >> 11551413

Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens.

J M Wroblewski1, D L Bixby, C Borowski, J R Yannelli.   

Abstract

A panel of 31 long-term non-small cell lung cancer (NSCLC) cell lines was examined for the expression of protein and/or mRNA transcripts for 11 distinct immune response related molecules or tumor associated antigens (TAA). To assess whether cytokine stimulation might up-regulate expression of the genes of interest, cells were cultured in 500 U/ml of gamma-interferon (gamma-IFN) for 48-72 h prior to analysis. Major histocompatibility complex (MHC) Class I antigens were detected by indirect immunofluorescence and were constitutively expressed on all of the cell lines. The average of the mean fluorescence intensity (MFI) measured 222+/-22. gamma-IFN stimulation produced a significant increase to 482+/-36. For MHC Class II only 7/31 cell lines (23%) exhibited constitutive expression, while gamma-IFN treatment had a dramatic effect and yielded 18/31 (58%) positive cell lines. The co-stimulatory molecules CD80 and CD86 were examined by direct immunofluorescence for cell surface expression and RT-PCR amplification for mRNA. CD80 protein was not detected at all, while an insignificant percentage of cells were positive (mean 2%) for CD86 in all cell lines tested. gamma-IFN had no apparent effect on CD80 or CD86 protein expression. Constitutive CD80 or CD86 mRNA levels were observed in 45 and 61% of the NSCLC lines, respectively. These percentages increased to 77% and 90% with gamma-IFN. Cell surface phenotypic analysis for TAA revealed positive populations in 28/31 cell lines (90%) for Her-2/neu, 18/31 (58%) for CEA and 8/31 (26%) for GD-2, with gamma-IFN having no effect. After gamma-IFN stimulation, RT-PCR amplification for Mage-1, -2, -3 and WT-1 detected mRNA in 33%, 33%, 44% and 70% of the cell lines, respectively. Overall, gamma-IFN stimulation led to the up-regulation of MHC Class I molecules and class II molecules as well as CD80 and CD86 mRNA transcripts. This survey represents the first comprehensive analysis of NSCLC cell lines for a variety of molecules that could play an important role in the generation of an NSCLC anti-tumor CD8+ cytotoxic T lymphocyte (CTL) response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551413     DOI: 10.1016/s0169-5002(01)00210-0

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  18 in total

1.  Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Authors:  Ben C Creelan; Scott Antonia; David Noyes; Terri B Hunter; George R Simon; Gerold Bepler; Charles C Williams; Tawee Tanvetyanon; Eric B Haura; Michael J Schell; Alberto Chiappori
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456

2.  Effective capture of circulating tumor cells from a transgenic mouse lung cancer model using dendrimer surfaces immobilized with anti-EGFR.

Authors:  Ja Hye Myung; Monic Roengvoraphoj; Kevin A Tam; Tian Ma; Vincent A Memoli; Ethan Dmitrovsky; Sarah J Freemantle; Seungpyo Hong
Journal:  Anal Chem       Date:  2015-09-10       Impact factor: 6.986

3.  Chemical and genetic control of IFNγ-induced MHCII expression.

Authors:  Ruud H Wijdeven; Marvin M van Luijn; Annet F Wierenga-Wolf; Jimmy J Akkermans; Peter J van den Elsen; Rogier Q Hintzen; Jacques Neefjes
Journal:  EMBO Rep       Date:  2018-07-18       Impact factor: 8.807

4.  Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses.

Authors:  Sofia R Gameiro; Jorge A Caballero; Jack P Higgins; David Apelian; James W Hodge
Journal:  Cancer Immunol Immunother       Date:  2011-05-05       Impact factor: 6.968

5.  Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells.

Authors:  Edward A Hirschowitz; Terry Foody; Giovanna E Hidalgo; John R Yannelli
Journal:  Lung Cancer       Date:  2007-05-16       Impact factor: 5.705

6.  Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy.

Authors:  Daniel W Fowler; John Copier; Natalie Wilson; Angus G Dalgleish; Mark D Bodman-Smith
Journal:  Cancer Immunol Immunother       Date:  2011-10-15       Impact factor: 6.968

Review 7.  The immunoregulatory mechanisms of carcinoma for its survival and development.

Authors:  Caigan Du; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-01-21

8.  Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer.

Authors:  Satoshi Hayashi; Takumi Kumai; Yoshiya Matsuda; Naoko Aoki; Keisuke Sato; Shoji Kimura; Masahiro Kitada; Masatoshi Tateno; Esteban Celis; Hiroya Kobayashi
Journal:  J Transl Med       Date:  2011-11-05       Impact factor: 5.531

9.  Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.

Authors:  Justin M Balko; Anil Potti; Christopher Saunders; Arnold Stromberg; Eric B Haura; Esther P Black
Journal:  BMC Genomics       Date:  2006-11-10       Impact factor: 3.969

10.  B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.

Authors:  Yixiang Mao; Wei Li; Kai Chen; Yufeng Xie; Qiang Liu; Min Yao; Weiming Duan; Xiumin Zhou; Rongrui Liang; Min Tao
Journal:  Oncotarget       Date:  2015-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.